We are live on ! Find out more
EUCRU

Eucrates Biomedical Acquisition Corp. Unit
EUCRU

Delisted

EUCRU was delisted on the 26th of April, 2023.

Back to rankings

4 hedge funds and large institutions have $6.72M invested in Eucrates Biomedical Acquisition Corp. Unit in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $6.51M → $6.72M (+$216K)

33% less funds holding

Funds holding: 6 → 4 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-2
Holders Change %
-33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$1.01K

Top Sellers

Rank Fund Capital Flow
1
WAM
Wolverine Asset Management
Illinois
-$26.3K
2
UBS Group
UBS Group
Switzerland
-$3.94K

EUCRU Hedge Fund Activity: Q1 2023 in Review

4 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q1 2023, worth a combined $6.72M — up 3.3% from $6.51M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of EUCRU and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Clear Street, adding an estimated $1.01K. The largest seller was Wolverine Asset Management, exiting entirely with an estimated $26.3K sold.

  • 4 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q1 2023, down from 6 in Q4 2022.
  • Funds reported $6.72M of Eucrates Biomedical Acquisition Corp. Unit stock for Q1 2023, up 3.3% quarter-over-quarter.
  • 0 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q1 2023 and 2 closed out, a net change of -2 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q1 2023 was Clear Street, an estimated $1.01K added.
  • The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q1 2023 was Wolverine Asset Management, an estimated $26.3K sold.

Based on aggregated 13F filings for Q1 2023.